Aliskiren disappoints in heart failure patients

Adding aliskiren to the standard therapy of patients hospitalized for heart failure with reduced left ventricular ejection fraction does not reduce their risk for cardiovascular mortality or readmission, shows the ASTRONAUT trial.
Source: MedWire News - Cardiology - Category: Cardiology Source Type: news